All In Biotech

Drug Trial Radar · NCT02636842

A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder

A Phase 1, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole Lauroxil Following Administration to the Deltoid or Gluteal Muscle in Adults With Schizophrenia or Schizoaffective Disorder

Last checked: Nov 20, 2026Latest source record: Jul 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

47

Actual

Start

Dec 2015

Primary completion

Jun 2016

Study completion Jun 2016

Sponsor

Lead sponsor
Alkermes, Inc.Industry
Sponsor type
Industry
First posted
Dec 22, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will determine the safety, tolerability, and pharmacokinetics of aripiprazole lauroxil in adults with schizophrenia or schizoaffective disorder.

Conditions

  • Schizophrenia
  • Schizoaffective Disorder

Interventions

  • Aripiprazole LauroxilDrug

    Intramuscular (IM) injection, single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum plasma concentration (Cmax)Time frame: Up to 7 days

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Alkermes Investigational Site

    Cerritos, California

  • Alkermes Investigational Site

    Lemon Grove, California

  • Alkermes Investigational Site

    Oakland, California

  • Alkermes Investigational Site

    Hoffman Estates, Illinois

  • Alkermes Investigational Site

    Marlton, New Jersey

  • Alkermes Investigative Site

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.